Colgate-Palmolive vs Procter & Gamble CL vs PG
Colgate-Palmolive and Procter & Gamble on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Debt / equity: Colgate-Palmolive 33.3×, Procter & Gamble 0.7×.
- Return on equity: Colgate-Palmolive 863.6%, Procter & Gamble 29.1%.
- Market value: Procter & Gamble $370.66B, Colgate-Palmolive $74.22B.
- Net margin: Procter & Gamble 18.2%, Colgate-Palmolive 9.7%.
Price return
2025-10-26 → 2026-10-26
CL+19.4%
PG+4.9%
Profile
latestSector
Consumer Defensive
Consumer Defensive
Industry
Household & Personal Products
Household & Personal Products
Market value
$74.22B
$370.66B
Enterprise value
$80.70B
$394.22B
Employees
33,600
104,000
Revenue per employee (TTM)
$626K
$845K
Our models
nightlythe valuation on each stock's pagePrice vs model
51% overvalued vs model
17% overvalued vs model
Model range
$34.82–151
$82.89–389
Models in the headline
1
1
FCF growth priced in, at a 10% return
11.5%
14.4%
Every model, its assumptions and its range: CL valuation · PG valuation. The growth priced in, at any return: CL reverse DCF · PG reverse DCF.
Trading
close 2026-10-26Last close
$93.10
$159.92
52-week high
$99.14
$167.20
52-week low
$74.98
$138.04
Price vs 52-week high
−6.1%
−4.4%
Price vs 52-week low
+24.2%
+15.9%
Average daily volume / shares
0.6%
0.4%
Beta
0.32
0.38
Returns
to 2026-10-261 month
+8.2%
+9.4%
3 months
+2.6%
+8.5%
6 months
+10.0%
+7.9%
Year to date
+17.8%
+11.6%
1 year
+19.4%
+4.9%
1 year, dividends added
+22.1%
+7.7%
2 years
−2.6%
−4.9%
Valuation
CL price × TTM to Jun 2026 · PG price × TTM to Sep 2026P/E (TTM)
36.8×
24.1×
P/E on consensus EPS (next FY)
24.1×
22.9×
Price / sales
3.5×
4.2×
EV / sales
3.8×
4.5×
EV / EBITDA
17.0×
16.1×
Price / book
314.5×
6.7×
Price / free cash flow (FY)
20.4×
24.5×
Free-cash-flow yield (FY)
4.9%
4.1%
Growth
CL TTM and FY2025 · PG TTM and FY2026Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+5.1%
+2.9%
Revenue, 3-year CAGR
4.3%
2.0%
Revenue, 5-year CAGR
4.4%
2.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+46.7%
+5.3%
EPS, 3-year CAGR
7.3%
3.9%
Free cash flow, 3-year CAGR
25.0%
3.2%
Diluted shares, 3-year change
−3.3%
−2.5%
Profitability
CL TTM to Jun 2026 · PG TTM to Sep 2026Gross margin (FY)†
60.1%
50.2%
Operating margin
15.8%
22.6%
EBITDA margin
22.6%
27.8%
Net margin
9.7%
18.2%
Free-cash-flow margin (FY)
17.8%
17.4%
Return on equity
863.6%
29.1%
Return on assets
12.1%
12.0%
Asset turnover
1.25
0.66
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
CL MRQ Jun 2026 · PG MRQ Sep 2026Cash
$1.37B
$15.37B
Total debt
$7.86B
$38.92B
Net debt
$6.49B
$23.56B
Debt / equity
33.3×
0.7×
Net debt / EBITDA (TTM)
1.4×
1.0×
Interest coverage (FY)
16.3×
22.5×
Current ratio (FY)
1.00
0.68
Dividends
trailing 12 monthsDividend yield
2.3%
2.7%
Dividends per share
$2.11
$4.32
Payout ratio (of TTM EPS)
83.4%
65.1%
Dividend per share, 5-year CAGR
3.3%
4.9%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
5
10
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$0
$8.3M
Analyst upgrades
0
2
Analyst downgrades
0
2
Statements
CL income TTM to Jun 2026 · cash flow FY2025 · PG income TTM to Sep 2026 · cash flow FY2026Revenue
$21.05B
$87.92B
EBITDA
$4.76B
$24.48B
Operating income
$3.32B
$19.83B
Net income
$2.04B
$16.03B
EPS (diluted)
$2.53
$6.64
Operating cash flow
$4.20B
$19.56B
Capital expenditure
−$564.0M
−$4.41B
Free cash flow
$3.63B
$15.15B
Dividends paid
$1.82B
$10.23B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.